EATG » Hepatitis

Hepatitis

New WHO scorecard shows poor progress of the viral hepatitis response in the African region

Brazzaville, Republic of Congo, June 14, 2019 – A new scorecard – the first to examine hepatitis prevalence and response in the World Health Organization (WHO) African region, shows that only…

Sustained Virologic Response in Patients With Chronic Hepatitis C and Liver Cancer

Continued efforts are needed to aggressively screen, diagnose, and treat hepatocellular carcinoma (HCC) because patients with chronic hepatitis C and HCC may be less likely to achieve cure status than those without…

Call for submissions to a compendium of good practice in the health sector response to viral hepatitis in the WHO European Region

WHO/Europe is appealing to Member States, partners and community organizations across the European Region to submit examples of good practice in response to viral hepatitis in the Region for publication…

Patient-Reported Symptoms During and After Direct Acting Antiviral Therapy for HCV

In real-world clinical practice, heterogeneous patient experiences occur during and after direct acting antiviral (DAA) therapy, and symptom improvement is often more pronounced in younger patients, according to a multicenter…

Fibronectin Predicts Seroclearance in Chronic Hepatitis B

Fibronectin may be a potential marker for hepatitis B surface antigen (HBsAg) seroclearance, according to study results published in The Journal of Infectious Diseases. A potentially achievable treatment end point for…

ContraVir announces CRV431 data from experimental model of hepatitis B

ContraVir Pharmaceuticals announces publication of CRV431 data from experimental model of hepatitis B EDISON, N.J., June 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development…

Checkmate for hepatitis B viruses in the liver

Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the…

WHO: Meeting global goals for HIV, hepatitis, STIs requires accelerated effort

More action is needed to meet goals to eliminate HIV, viral hepatitis, and sexually transmitted infections by 2030, according to a recently released World Health Organization (WHO) progress report. The…

Just 18% of people with hepatitis/HIV co-infection and cirrhosis are screened for liver cancer as often as recommended

There is a “strikingly low adherence” to clinical guidelines for ultrasound screening for hepatocellular carcinoma in Western Europe, researchers report in the Journal of Viral Hepatitis. Over years or decades,…

Elbasvir/Grazoprevir: First-Line Therapy for Chronic HCV in DAA-Naive Patients?

Elbasvir (EBR) combined with grazoprevir (GZR) may be extremely useful as first-line therapy for chronic hepatitis C virus (HCV) infection in patients who are direct-acting antiviral (DAA) treatment-naive, according to…

1 2 3 112